Ľubica Váleková, Juraj Chudej
Malignant lymphomas (ML) represent a group of oncologic disorders with significant progress in the field of their diagnostics and also their treatment. The modern approach to patient is based on an effort of individual tumour behaviour knowledge and the assumed risk of unprocurable complete remission after conventional chemotherapy, the risk of relapse or short overall survival of patients. On the basis of combined modern prognostic factors we can select individual intensive therapy in younger patients, decrease the toxicity of the treatment in patients with the low-risk disease and increase the probable survival in patients with the advanced and high-risk disease. The strategy of treatment with the curative intention is chosen in majority of cases. Due to progress in diagnostics, staging and mainly new possibilities of biological treatment, malignant lymphomas have become one of the most treatable and, in an increasing number, curable tumours as well. Treatment of each patient is individual and it mainly depends on the type of lymphoma and the extent of the disease - on its stage and risk factors.